Who Should Use Teriparatide?
Teriparatide is indicated for the treatment of osteoporosis in both men and women who are at high risk for fracture. This includes men and postmenopausal women with a history of an osteoporotic fracture or who have multiple risk factors for fracture, men with primary or hypogonadal osteoporosis, and those who have failed or are intolerant of previous osteoporosis therapy. The effects on risk for fracture in men have not been studied. Safety Information The safety and efficacy of teriparatide have not been evaluated beyond 2 years. In 2- year studies in rats, teriparatide caused an increase in the incidence of osteosarcoma, a malignant bone tumor, which was dependent on dose and duration of treatment. There have been no reported cases in patients who received teriparatide in clinical trials and therefore it is not known if humans are at an increased risk for this cancer while using this drug. Teriparatide will have a black box warning in the package insert regarding the osteosarcoma fin
